Classes
- Clinical 10 days - Department of Oncology +1D0110ONK | Second Faculty of Medicine
- Clinical Radiotherapy +1D0503007 | Second Faculty of Medicine
- Radiotherapy +1D0505002 | Second Faculty of Medicine
- Clinical Radiotherapy - Training +1D0505009 | Second Faculty of Medicine
- OS - Selected chapters from oncologyDVA1099 | Second Faculty of Medicine
Publications
- Evaluation of Anti-cancer Therapies with Reimbursement Limited to Comprehensive Cancer Centres Using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale2017 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry2017 | First Faculty of Medicine
- Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer: An International Collaborative Study2017 | Publication without faculty affiliation
- Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression(aEuro)2016 | Publication without faculty affiliation
- Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry2015 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry2015 | First Faculty of Medicine
- Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study2015 | First Faculty of Medicine
- Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer2015 | Publication without faculty affiliation
- Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy2015 | Publication without faculty affiliation
- Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data2015 | Publication without faculty affiliation
Loading network view...